金迪克：预计2025年全年净亏损1.60亿元—1.80亿元

Core Viewpoint - The company, Jindike, forecasts a significant net loss for the year 2025, with expected net profit attributable to shareholders ranging from -160 million to -180 million yuan, indicating a year-on-year increase in losses of 71.12% to 92.51% [1] Financial Performance - The company anticipates a sales revenue of approximately 112 million yuan for 2025, showing a certain degree of growth compared to the previous year [1] - The expected net profit excluding non-recurring losses is projected to be between -165 million and -185 million yuan [1] Reasons for Performance Changes - The company has increased production efficiency through early production scheduling, enhanced equipment maintenance, and improved labor discipline, which has contributed to the acceleration of flu vaccine production and shipment [1] - The company is facing increased research and development costs due to the ongoing Phase III clinical trials for the quadrivalent flu virus split vaccine (for children) and the submission of production applications for the trivalent flu virus split vaccine [1] - There are risks associated with in-process and finished products due to equipment failures and material batch differences, leading the company to decide against selling certain products [1] - The quadrivalent flu virus split vaccine has a shelf life of 12 months, necessitating the disposal of unadministered vaccines at the end of each flu season, which has resulted in asset impairment provisions totaling approximately 41.99 million yuan [1]